The global leukemia therapeutics market is expected to register a CAGR of 5.5% during the forecast period, 2018 to 2023. North America dominates the market, due to increasing prevalence of leukemia and the rising healthcare expenditure in the region.
Rise in Number of Leukemia Patients Worldwide
Leukemia is the eleventh most common cancer worldwide and in 2012, accounted for nearly 352,000 new cases. In 2014, an estimated 387,728 people were living with leukemia in the United States. Leukemia is common among children, however it often occurs in adults. Leukemia is marginally more common in men than in women. The number of new cases of leukemia was 13.7 per 100,000 men and women per year, based on cases from 2010 to 2014. Acute Lymphocytic Leukemia (ALL) is the most common form of leukemia, and it is estimated that the number of new cases recorded is around 1.7 per 100,000 men and women per year. Additionally, innovative therapies for leukemia treatment, rising investment in healthcare sectors, and high unmet need for curative cancer therapy are likely to drive the market growth.
Stringent Regulatory Scenario
Research is currently being conducted for the development of cancer therapeutics, particularly cancer vaccines and targeted therapy for leukemia. However, the entry of new anticancer treatments into clinical trials is restricted by the strict regulatory principles of drug safety and marketing. Regulatory authorities such as the Food and Drug Administration (FDA, USA), European Medicines Agency (EMA, EU), Japanese Pharmaceuticals and Medical Devices Agency (Japan), Australian Therapeutics Goods Administration (Australia), Health Canada (Canada), and regulatory authorities of other countries have strict regulations regarding the marketing of new drugs. This has greatly impacted the growth of the cancer therapeutics market. Additionally, the high cost of treatment is likely to impede the market growth of the global leukemia therapeutics market.
North America to Dominate the Market
North America is anticipated to register the highest share in 2017 in global leukemia therapeutics market. The development and availability of advanced therapeutics in the region and the rising expenditure toward healthcare is augmenting the market growth in the region. The Asia-Pacific region is anticipated to register a high growth rate during the forecast period, owing to rising prevalence of leukemia, and growing market of generic drugs in the region.
Key Developments in the Market
- August 2017: The Food and Drug Administration approved Kymriah, the first gene therapy treatment for leukemia.
- August 2017: The Food and Drug Administration approved two new treatments for few adult patients with acute myeloid leukemia (AML), enasidenib (Idhifa), a drug that targets aberrant forms of the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos), a two-drug chemotherapy combination encapsulated in tiny fatlike particles called liposomes.
Major Players: Biogen Idec Inc., Bristol-Myers Squibb, Celgene Corporation, Cephalon Inc., Eisai Co. Ltd, Genzyme Corporation, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA, among others.
Reasons to Purchase the Report
- Current and future global leukemia therapeutics market outlook in the developed and emerging markets
- Analysis of various perspectives of the market with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players
- 3-month analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
- This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Rise in Number of Leukemia Patients Worldwide
6.1.2 Innovative Therapies
6.1.3 Rising Investment in Healthcare Sectors
6.1.4 High Unmet Need for Cancer Therapy
6.2 Market Restraints
6.2.1 High Cost of Treatment and Adverse Effects
6.2.2 Stringent Regulatory Scenario
6.4 Key Challenges
7. Market Segmentation
7.1 By Drug
7.1.2 Alkylating Agents
7.1.3 Monoclonal Antibodies
7.2 By Type of Leukemia
7.2.1 Acute Lymphoblastic Leukemia
7.2.2 Acute Myeloid Leukemia
7.2.3 Chronic Lymphocytic Leukemia
7.2.4 Chronic Myelogenous Leukemia
7.3 By Geography
7.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest Of Europe
18.104.22.168 Australia & New Zealand
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
7.3.4 Middle East & Africa
188.8.131.52 GCC Countries
184.108.40.206 South Africa
220.127.116.11 Rest of the Middle East & Africa
7.3.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Biogen Idec Inc.
9.2 Bristol-Myers Squibb Company
9.3 Celgene Corporation
9.4 Cephalon Inc.
9.5 Eisai Co. Ltd
9.6 Genzyme Corporation
9.7 GlaxoSmithKline plc
9.8 Novartis AG
9.9 Pfizer Inc.
9.10 Sanofi SA
10. Future of the Market